Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

Ongoing, but not recruiting

2

Start Date 09/01/2013

Age of Trial (yrs) 11.3

Gleevec-resistant

EGFR and VEGF inhibitor

Block related tumor signal paths

Specifically GIST and only GIST

130208, 13-C-0208

National Cancer Institute (NCI)

Claudia P Derse-Anthony (301) 402-0199 derseanthonycp@mail.nih.gov CFernanda I Arnaldez, M.D (301) 451-7014 arnaldezf@mail.nih.gov

Oral

Age:

-greater than or equal to 3 years of age and BSA greater than or equal to 0.5 m(2)

Diagnosis

Histologically or cytologically confirmed GIST by the Laboratory of Pathology, NCI.
Absence of Kit and PDGFRA mutation confirmed in a CLIA certified laboratory.
Participants must have measurable disease as defined in RECIST (v1.1) as the presence of at least one lesion not previously irradiated, that can be accurately measured at baseline greter than or equal to 10mm in the longest diameter (except lymph nodes which must have short axis greater than or equal to 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.